Form 4: Pulmonx Corp Interim CFO John McKune Reports Stock Transactions
SEC Form 4 Filing
Interim CFO of Pulmonx Corp, John McKune, reports the acquisition and disposal of common stock and stock options.
Summary
- On March 1, 2024, John McKune, Interim CFO of Pulmonx Corp, reported transactions involving the company's common stock and stock options.
- McKune sold 155 shares at $9.06 to cover tax obligations related to RSUs vesting from a June 1, 2021 grant.
- He also sold 254 shares at $9.06 to cover tax obligations related to RSUs vesting from a March 1, 2022 grant.
- An additional 669 shares were sold at $9.06 to cover tax obligations related to RSUs vesting from a March 1, 2023 grant.
- McKune acquired 14,400 shares through an RSU grant that vests quarterly over four years, starting March 1, 2024.
- He also acquired an option to buy 28,800 shares at $9.30, vesting monthly over 48 months starting March 1, 2024.
- Following these transactions, McKune directly owns 61,810 shares of common stock and options for 28,800 shares.
Sentiment
Score: 6
Explanation: Neutral sentiment as the transactions appear to be routine and related to compensation and tax obligations. The acquisition of RSUs and options is a positive sign, but the sale of shares tempers the overall sentiment.
Positives
- McKune received a grant of 14,400 RSUs, indicating continued alignment with the company's long-term success.
- He also received an option to purchase 28,800 shares, further aligning his interests with shareholders.
Negatives
- McKune sold 1,078 shares to cover tax obligations, which could be interpreted as a slight lack of confidence, although it's a common practice.
Risks
- The sale of shares, even for tax purposes, could be perceived negatively by some investors.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to track management's sentiment and actions regarding the company's stock.
Comparison to Industry Standards
- Insider transactions are a common occurrence in publicly traded companies.
- The vesting schedules and option grants are typical compensation practices to align management's interests with shareholders.
- Comparable companies in the medical device space also utilize stock options and RSUs as part of their compensation packages.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding insider activity.
- Employees holding stock options and RSUs are impacted by the vesting schedules and stock price.
Key Dates
| Date | Description |
|---|---|
| 06/01/2021 | Date of RSU grant related to some of the shares sold. |
| 03/01/2022 | Date of RSU grant related to some of the shares sold. |
| 03/01/2023 | Date of RSU grant related to some of the shares sold. |
| 02/21/2024 | Reporting Person acquired 841 shares under the Issuer's 2020 Employee Stock Purchase Plan. |
| 02/28/2034 | Expiration date of the Employee Stock Option. |
| 03/01/2024 | Date of the reported transactions, including sales and acquisitions of stock and options; vesting start date for RSUs and stock options. |
| 03/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.